Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - Piper Sandler has lowered its price target on Privia Health Group Inc (NASDAQ:PRVA) to $35.00 from $36.00 while maintaining an Overweight rating on the stock. The new target represents a 70% upside from the current price of $20.58. According to InvestingPro data, analysts maintain a strong buy consensus with a 1.38 rating.
The price target adjustment represents a $1.00 reduction from the investment firm’s previous valuation of the healthcare company.
Despite the slight decrease in price target, Piper Sandler has chosen to maintain its Overweight rating, indicating the firm still has a positive outlook on Privia Health’s potential performance.
Piper Sandler characterized Privia as "the baby in the VBC bathwater," suggesting the company stands out within the value-based care sector.
The firm also described potential investors as "buyers of large 2Q25 beat and raise," indicating expectations for Privia to exceed second-quarter 2025 financial projections.
In other recent news, Privia Health Group Inc. announced its Q2 2025 earnings, which revealed a mixed performance. The company reported an earnings per share (EPS) of $0.02, which fell short of analysts’ expectations of $0.05, marking a 60% negative surprise. Despite this, Privia Health exceeded revenue forecasts, achieving $521.15 million compared to the anticipated $467.03 million, representing an 11.59% positive surprise. This financial performance highlights a discrepancy between earnings and revenue outcomes for the quarter. The earnings report has drawn attention from investors, with market reactions reflecting the mixed results. Analyst firms have not yet publicly issued upgrades or downgrades following the earnings announcement. These recent developments are significant for stakeholders monitoring Privia Health’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.